Benzinga - During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the healthcare sector.
Pfizer Inc. (NYSE: PFE) Dividend Yield: 3.86%
- SVB Leerink analyst David Risinger maintained a Market Perform rating and cut the price target from $49 to $48 on Feb. 1, 2023. This analyst has an accuracy rate of 75%.
- Mizuho analyst Vamil Divan maintained a Neutral rating on the stock and raised the price target from $44 to $56 on Dec. 14, 2021. This analyst has an accuracy rate of 74%.
- Recent News: Pfizer said the US Food and Drug Administration granted Priority Review for the company's Biologics License Application (BLA) for elranatamab. The European Medicines Agency also accepted elranatamab's marketing authorization application.
- Dividend Yield: 3.80%
- DZ Bank analyst Elmar Kraus downgraded the stock from Buy to Hold on Feb. 11, 2022. This analyst has an accuracy rate of 70%.
- Barclays analyst Emily Field upgraded the stock from Underweight to Equal-Weight on Nov. 5, 2021. This analyst has an accuracy rate of 67%.
- Recent News: Vir Biotechnology announced amended collaboration agreement with GSK.
- Dividend Yield: 3.93%
- SVB Leerink analyst David Risinger upgraded the stock from Underperform to Market Perform and raised the price target from $135 to $153 on Feb. 10, 2023. This analyst has an accuracy rate of 75%.
- Goldman Sachs analyst Chris Shibutani maintained a Neutral rating and increased the price target from $122 to $140 on April 12, 2022. This analyst has an accuracy rate of 72%.
- Recent News: AbbVie reported Q4 adjusted EPS of $3.60, up 16.9% Y/Y and beating the consensus of $3.56.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.